Health
Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape
The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.
After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…
-
Noosa News14 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General18 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General7 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Business23 hours agoTop brokers name 3 ASX shares to buy next week 5 October 2025